Cover Image
市場調查報告書

乾癬性關節炎的全球市場 (2015∼2019年)

Global Psoriatic Arthritis Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 347468
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
乾癬性關節炎的全球市場 (2015∼2019年) Global Psoriatic Arthritis Market 2015-2019
出版日期: 2015年12月16日 內容資訊: 英文 101 Pages
簡介

所謂乾癬性關節炎,是在人體的遠位關節和骨盆的背面、薦腸關節產生的慢性發炎性疾病。一般認為全球乾癬性關節炎的患者數有緩慢的增加趨勢,而且隨之治療藥的市場規模今後也將穩定地成長。還有各種新產品也開發、上市,推動了市場成長。在各地區中,南北美洲佔全球整體的40%以上。

本報告提供全球乾癬性關節炎的市場相關分析、疾病概要和市場結構、主要的開發中產品與其特長、市場規模趨勢 (今後5年的預測值)、藥物的各類型 (劑形、給藥途徑、作用機制等) 及各地區詳細趨勢、推動&阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 產品簡介

第4章 市場分析技術

  • 分析方法
  • 經濟指標

第5章 簡介

  • 市場趨勢的概要

第5章 市場環境

  • 市場結構
  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第6章 疾病概要

  • 疾病的基礎知識
  • 乾癬性關節炎的種類
  • 症狀
  • 風險要素
  • 診斷
  • 疾病管理
  • QoL (生活品質)
  • 流行病學

第7章 開發中產品簡介

第8章 開發平台候補藥新的標的、作用機制

  • 小分子
  • 生技藥品

第9章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第10章 各作用機制 (MoA) 的市場區隔

  • 腫瘤壞死因子 (TNF) -α抑制劑
  • PDE4 (PDE4) 抑制劑
  • 白細胞介素 (IL) 阻斷劑
  • 其他

第11章 各分子類型的市場區隔

  • 生技藥品
  • 小分子

第12章 疾病的各重症度的市場區隔

第13章 各投藥途徑的市場區隔

  • 口服藥
  • 非口服藥
  • 局部給藥

第14章 各劑形的市場區隔

  • 固體
  • 液體
  • 半固體

第15章 地區區分

  • 南北美洲市場
  • 歐洲、中東、非洲各國 (EMEA) 市場
  • 亞太地區市場

第16章 推動市場要素

  • 一般認知度的上升
  • 醫療上的未滿足需求
  • 患者人口的增加
  • 生活模式的變化

第17章 推動因素的影響力

第18章 市場課題

  • 生技藥品的成本上升
  • 品牌藥的專利到期
  • 患者的補充/替代療法 (CAM) 的利用
  • 藥物的副作用

第19章 推動因素、課題的影響力

第20章 市場趨勢

  • 生技仿製藥的登場
  • 非適應症/傳統選擇受歡迎
  • 美國的患者支援計劃
  • 生技藥品壟斷市場

第21章 供應商環境

  • 競爭方案
  • 市場佔有率分析
  • 其他卓越供應商

第22章 主要供應商分析

  • AbbVie
  • Amgen
  • Celgene
  • Janssen Pharmaceuticals
  • UCB

第23章 附錄

  • 簡稱集

第24章 關於Technavio

圖表一覽

目錄
Product Code: IRTNTR7499

Market outlook of the psoriatic arthritis market

Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis. The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market. Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.

In this market research report, Technavio analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.

Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers

The TNF inhibitors aid in suppressing the inflammatory response in the patient's body. These inhibitors are used to manage diseases like rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and seronegative spondyloarthropathies. Moreover, its ability to use a targeted mechanism to treat most of the inflammatory and autoimmune diseases is primarily responsible for its high market share of almost 80% by 2019.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

  • TNF inhibitors
  • PDE4 inhibitors
  • Interleukin blockers
  • Others

Segmentation by type of disease and analysis of: mild, moderate, & severe psoriatic arthritis

The mild psoriatic arthritis segment accounts for more than 60% of all the diagnosed cases and is the most common type of psoriatic arthritis in patients across the globe. This condition affects less than four joints in the body and is also known as oligoarticular arthritis.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

  • Mild psoriatic arthritis
  • Moderate psoriatic arthritis
  • Severe psoriatic arthritis

Competitive landscape and key vendors: Abbvie, Amgen, Janssen Pharmaceuticals

This market is primarily dominated by large vendors due to their extensive product portfolios. The company that manufactures and markets a drug that can treat psoriatic arthritis, and also exhibit a high safety and efficacy profile, is expected to gain a competitive advantage over its rivals during the forecast period.

Leading vendors in this market are -

  • Abbvie
  • Amgen
  • Janssen Pharmaceuticals
  • Celgene
  • UCB

Other prominent vendors analyzed in this market study are Alder Biopharmaceuticals, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hofffmann-La Roche, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Takeda Pharmaceutical.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2019?
  • What are the key factors driving the psoriatic arthritis market?
  • What are the key market trends impacting the growth of the psoriatic arthritis market?
  • What are the challenges to market growth?
  • Who are the key vendors in the psoriatic arthritis market?
  • What are the market opportunities and threats faced by the vendors in the psoriatic arthritis market?
  • Trending factors influencing the market shares of APAC, EMEA, and the Americas?
  • What are the key outcomes of the five forces analysis of the psoriatic arthritis market?

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Product profiles

PART 04: Market research methodology

  • Research methodology
  • Economic indicators

PART 05: Introduction

  • Key market highlights

PART 06: Disease overview

  • Understanding the disease
  • Types of psoriatic arthritis
  • Symptoms
  • Risk factors
  • Diagnosis
  • Disease management
  • Quality of life
  • Epidemiology

PART 07: Pipeline portfolio

PART 08: Novel mechanisms targeted by pipeline candidates

  • Small molecules
  • Biologics

PART 09: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 10: Market segmentation by MoA

  • TNF-alpha inhibitors
  • PDE4 inhibitors
  • IL blockers
  • Others

PART 11: Market segmentation by type of molecule

  • Biologics
  • Small molecules

PART 12: Market segmentation by severity of disease

PART 13: Market segmentation by route of administration

  • Oral
  • Parenteral
  • Topical

PART 14: Market segmentation by dosage form

  • Solid
  • Liquid
  • Semi-solid

PART 15: Geographical segmentation

  • Psoriatic arthritis market in Americas
  • Psoriatic arthritis market in EMEA
  • Psoriatic arthritis market in APAC

PART 16: Market drivers

  • Increase in public awareness
  • Unmet medical needs
  • Growing patient population
  • Change in lifestyle patterns

PART 17: Impact of drivers

PART 18: Market challenges

  • Increasing costs of biologics
  • Loss of patent exclusivity of branded therapies
  • Use of CAM by patients
  • Adverse effects of drugs

PART 19: Impact of drivers and challenges

PART 20: Market trends

  • Emergence of biosimilars
  • Popularity of off-label and traditional treatment options
  • Patient assistance programs in the US
  • Dominance of market by biologics

PART 21: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 22: Key vendor analysis

  • AbbVie
  • Amgen
  • Celgene
  • Janssen Pharmaceuticals
  • UCB

PART 23: Appendix

  • List of abbreviations

PART 24: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings 7
  • Exhibit 02: Types of psoriatic arthritis
  • Exhibit 03: Signs and symptoms of psoriatic arthritis
  • Exhibit 04: Risk factors for psoriatic arthritis
  • Exhibit 05: Diagnostic test for psoriatic arthritis
  • Exhibit 06: Treatment options for psoriatic arthritis
  • Exhibit 07: Management of psoriatic arthritis
  • Exhibit 08: Pipeline molecules for psoriatic arthritis
  • Exhibit 09: Psoriatic arthritis clinical trial by phase
  • Exhibit 10: Psoriatic arthritis clinical trial by status
  • Exhibit 11: Novel targets of the pipeline candidates
  • Exhibit 12: Tofacitinib
  • Exhibit 13: Ixekizumab
  • Exhibit 14: Sekukinumab
  • Exhibit 15: Bimekizumab
  • Exhibit 16: Global psoriatic arthritis market 2014-2019 ($ millions)
  • Exhibit 17: Five forces analysis
  • Exhibit 18: Segmentation of global psoriatic arthritis market by MoA
  • Exhibit 19: Segmentation of global psoriatic arthritis market by MoA 2014
  • Exhibit 20: Segmentation of global psoriatic arthritis market by type of molecule
  • Exhibit 21: Segmentation of global psoriatic arthritis market by severity of disease
  • Exhibit 22: Segmentation of global psoriatic arthritis market by route of administration
  • Exhibit 23: Segmentation of global psoriatic arthritis market by dosage form
  • Exhibit 24: Global psoriatic arthritis market by geography 2014
  • Exhibit 25: Psoriatic arthritis market in Americas 2014-2019 ($ millions)
  • Exhibit 26: Psoriatic arthritis market in EMEA 2014-2019 ($ millions)
  • Exhibit 27: Psoriatic arthritis market in APAC 2014-2019 ($ millions)
  • Exhibit 28: Global psoriatic arthritis market by geography 2014-2019 ($ millions)
  • Exhibit 29: Drivers in global psoriatic arthritis market
  • Exhibit 30: Impact of drivers
  • Exhibit 31: Challenges in global psoriatic arthritis market
  • Exhibit 32: Average annual cost of HUMIRA, Enbrel, and Remicade 2014 ($)
  • Exhibit 33: Approvals and patent expiries of branded biologics
  • Exhibit 34: Impact of drivers and challenges
  • Exhibit 35: Trends in global psoriatic arthritis market
  • Exhibit 36: YoY sales comparison of top drugs 2010-2014 ($ millions)
  • Exhibit 37: YoY sales comparison of top drugs 2010-2014 (%)
  • Exhibit 38: YoY global sales of HUMIRA 2010-2014 ($ millions)
  • Exhibit 39: AbbVie: Key takeaways
  • Exhibit 40: YoY global sales of Remicade 2010-2014 ($ millions)
  • Exhibit 41: YoY global sales of Simponi 2012-2014 ($ millions)
  • Exhibit 42: Janssen Pharmaceuticals: Key takeaways
  • Exhibit 43: YoY sales of Enbrel in US and Canada 2010-2014 (($ millions)
  • Exhibit 44: YoY sales of Enbrel in US 2010-2014 ($ millions)
  • Exhibit 45: YoY sales of Enbrel in Canada 2010-2014 ($ millions)
  • Exhibit 46: YoY sales of Enbrel in Japan 2010-2014 ($ millions)
  • Exhibit 47: Comparison of YoY sales of Enbrel in US, Japan, and Canada 2010-2014 ($ millions)
  • Exhibit 48: Amgen: Key takeaways
  • Exhibit 49: UCB: Key takeaways
  • Exhibit 50: Celgene: Key takeaways
  • Exhibit 51: AbbVie: Product segmentation by revenue 2014
  • Exhibit 52: AbbVie: Geographical segmentation by revenue 2014
  • Exhibit 53: Amgen: Business segmentation by revenue 2014
  • Exhibit 54: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 55: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 56: Celgene: Product segmentation by revenue 2014
  • Exhibit 57: Celgene: Product segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 58: Celgene: Geographical segmentation by revenue 2014
  • Exhibit 59: Janssen Pharmaceuticals: Key therapeutic areas
  • Exhibit 60: UCB: Product segmentation by revenue 2014
  • Exhibit 61: UCB: Product segmentation by revenue 2013 and 2014
  • Exhibit 62: UCB: Geographical segmentation by revenue 2014
  • Exhibit 63: Geographical segmentation by revenue 2013 and 2014
Back to Top